



Dear Rett Syndrome Community,

The pandemic has created a series of unprecedented challenges, particularly to clinical research. While some of these challenges are common across all clinical studies, others are unique to the randomized, controlled study of cannabidiol oral solution in patients with Rett syndrome (GWND18064).

After carefully evaluating global study progress to date and the ongoing impact of the pandemic to patients, caregivers, and research sites, GW has made the difficult decision to discontinue study GWND18064. The data collected from this trial were blinded, and therefore were not part of the decision to discontinue the trial. We understand that this news will be met with disappointment by the community. Unfortunately, the significant challenges to conducting this trial have been magnified by the pandemic leading to the conclusion that it is no longer feasible to conduct this study.

We are very grateful to the Rett community for their collaboration, partnership, and support of this project. We fully appreciate the great deal of effort and dedication by clinicians, study personnel and most importantly, patients and caregivers to support this trial. We recognize the significant unmet need currently experienced by individuals living with Rett syndrome and their families, and we are deeply disappointed that the study will not be able to continue.

Patients already participating in the randomized study or awaiting entry into the open-label extension (OLE) study, should contact their study physician with questions and to discuss their options.

For non-study related questions, please contact us at medinfo@gwpharm.com.

Kind regards,
GW Pharmaceuticals